Immuneering
Immuneering is a clinical-stage oncology company focused on developing universal-RAS/RAF medicines for broad populations of cancer patients, with its lead candidate IMM-1-104 currently in Phase 1/2a trials.
Company Overview
Immuneering is a clinical-stage oncology company focused on developing and commercializing universal-RAS/RAF medicines for a broad population of cancer patients. Its proprietary platform leverage human biological data, bioinformatics, and computational biology to inform every stage of the drug development process. The company's robust pipeline includes several novel drug programs, with IMM-1-104 as its lead candidate targeting tumors driven by RAS mutations.
Lead Product Candidate: IMM-1-104
IMM-1-104 is Immuneering's lead clinical-stage candidate designed to achieve universal-RAS activity, selectively targeting cancer cells more than healthy cells. It operates through Deep Cyclic Inhibition of the MAPK pathway and is administered once daily. Currently, IMM-1-104 is being evaluated in a Phase 1/2a trial for patients with advanced solid tumors harboring RAS mutations.
Pipeline Development: IMM-6-415
In addition to IMM-1-104, Immuneering's development pipeline includes IMM-6-415, a Deep Cyclic Inhibitor administered twice daily. IMM-6-415 is currently under evaluation in a Phase 1/2a trial, targeting patients with advanced solid tumors that harbor RAF or RAS mutations.
Proprietary Technology Platform
Immuneering has developed a proprietary, disease-agnostic platform that integrates bioinformatics and computational biology into the drug development process. This platform uses humanized preclinical models and Fluency deep learning AI technology to identify small molecules that selectively bind to targets of interest. The platform is designed to derive counterintuitive insights not constrained by conventional approaches, enabling the discovery of novel targets and new ways to drug existing targets using Disease Cancelling Technology.
Company Locations and Employee Benefits
Immuneering operates locations in Cambridge, MA; New York, NY; and San Diego, CA. The company offers full-time employees a comprehensive PPO medical plan with no premium charge, including dental and vision plans, and other wellness benefits. Additionally, Immuneering provides a 401(k) savings plan with a 1:1 matching feature that begins immediately upon employment.